Responses
Clinical and epidemiological research
Extended report
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Compose a Response to This Article
Other responses
No responses have been published for this article.